The Cooper Companies, Inc. $COO Holdings Boosted by Pekin Hardy Strauss Inc.

Pekin Hardy Strauss Inc. lifted its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 11.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 80,419 shares of the medical device company’s stock after acquiring an additional 8,124 shares during the quarter. Pekin Hardy Strauss Inc.’s holdings in Cooper Companies were worth $4,546,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Algert Global LLC bought a new stake in shares of Cooper Companies during the 2nd quarter worth approximately $7,655,000. Bank of America Corp DE acquired a new stake in shares of Cooper Companies in the 2nd quarter valued at approximately $144,125,000. BlackRock Inc. acquired a new stake in shares of Cooper Companies in the 2nd quarter valued at approximately $1,077,762,000. National Pension Service grew its stake in shares of Cooper Companies by 9,314.0% in the second quarter. National Pension Service now owns 526,149 shares of the medical device company’s stock valued at $37,730,000 after buying an additional 520,560 shares in the last quarter. Finally, Arizona State Retirement System grew its stake in shares of Cooper Companies by 108.2% in the second quarter. Arizona State Retirement System now owns 110,873 shares of the medical device company’s stock valued at $7,951,000 after buying an additional 57,621 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Stock Performance

Shares of NASDAQ COO opened at $63.51 on Friday. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $12.08 billion, a P/E ratio of 21.68, a P/E/G ratio of 2.53 and a beta of 0.83. The Cooper Companies, Inc. has a 12 month low of $51.01 and a 12 month high of $89.83. The stock has a 50 day moving average of $59.37 and a 200-day moving average of $68.70.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The business had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.10 billion. During the same quarter in the prior year, the business earned $0.49 EPS. The firm’s revenue for the quarter was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities research analysts predict that The Cooper Companies, Inc. will post 4.53 EPS for the current year.

Cooper Companies announced that its Board of Directors has initiated a stock buyback program on Wednesday, September 9th that authorizes the company to repurchase $3 billion in shares. This buyback authorization authorizes the medical device company to repurchase up to 22.7% of its shares through open market purchases. Stock buyback programs are typically an indication that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on COO shares. Barclays upgraded shares of Cooper Companies to a “hold” rating in a report on Wednesday, October 7th. Piper Sandler reiterated a “neutral” rating on shares of Cooper Companies in a research note on Thursday, October 15th. Wall Street Zen downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a research report on Saturday, September 12th. Robert W. Baird set a $61.00 price objective on shares of Cooper Companies and gave the company a “neutral” rating in a research report on Thursday, September 10th. Finally, Citigroup restated a “neutral” rating and set a $60.00 price objective (down from $80.00) on shares of Cooper Companies in a research note on Thursday, September 10th. Four investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $68.60.

Insider Buying and Selling at Cooper Companies

In related news, Director Lawrence Kurzius acquired 10,000 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were bought at an average cost of $53.91 per share, with a total value of $539,100.00. Following the completion of the transaction, the director directly owned 21,099 shares of the company’s stock, valued at $1,137,447.09. This trade represents a 90.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Paul Keel bought 4,701 shares of the business’s stock in a transaction dated Friday, September 11th. The shares were bought at an average price of $53.18 per share, with a total value of $249,999.18. Following the purchase, the director owned 4,701 shares in the company, valued at $249,999.18. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 34,701 shares of company stock worth $1,880,039 over the last ninety days. Insiders own 2.08% of the company’s stock.

Cooper Companies Company Profile

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.